Securing Federal Validation for a Next-Generation Epigenetic Diagnostic Platform
Over $300K awarded | NIH Phase I SBIR
Services: Grant Strategy, Application Development, Federal Funding Advisory
Overview
A pioneering epigenetic diagnostics company had developed a novel systems-based framework for mapping how DNA methylation changes over time — work with significant implications for chronic disease prediction, personalized treatment, and drug discovery. To advance the science, they needed federal funding and the credibility that comes with it. BW&CO partnered with the company to build and execute a competitive NIH SBIR application strategy, resulting in a Phase I award of over $300K that validated the technology and opened the door to the next stage of research and commercialization.
The Challenge
The company had genuine scientific differentiation — a dynamic, longitudinal approach to epigenomic modeling that stood apart from the static diagnostic tools dominating the market. But translating cutting-edge science into a winning federal grant application is a distinct discipline, and one where many promising companies fall short. NIH SBIR applications demand rigorous alignment between scientific narrative, commercial viability, and program priorities. The stakes were high: securing this award wasn't just about funding — it was about earning institutional recognition that would strengthen future fundraising, research partnerships, and market positioning.
The engagement required deep collaboration between BW&CO's grant strategy team and the client's scientific leadership to ensure the application accurately represented the innovation while meeting the exacting standards federal reviewers expect.
Our Approach
BW&CO led the full application development process across several interconnected workstreams:
Opportunity Assessment & Program Alignment: Evaluated NIH funding priorities and SBIR program fit to identify the strongest submission pathway for the client's technology and research objectives
Scientific Narrative Development: Worked closely with the research team to translate complex epigenomic concepts into a clear, compelling narrative structured for federal peer review
Commercial Viability Framing: Developed the commercialization and market sections required by SBIR, articulating the pathway from Phase I research to real-world clinical and therapeutic applications
Application Writing & Editing: Drafted, reviewed, and refined all application components to meet NIH formatting, compliance, and scoring criteria
Submission Management: Managed the submission process end-to-end, ensuring accuracy and on-time delivery
Results
BW&CO's engagement resulted in a successful NIH Phase I SBIR award of over $300K — a competitive outcome that reflects both the strength of the underlying science and the quality of the application. The funding will support development of the company's systems-based epigenomic modeling framework, with initial targets in cardiovascular disease, type 2 diabetes, and mortality risk prediction.
Beyond the immediate award, the NIH imprimatur positions the company to pursue Phase II SBIR funding, attract institutional research partners, and strengthen its standing with private investors. Federal recognition at this level signals scientific legitimacy in a way that few other milestones can — and it sets the stage for the company to advance from early-stage innovation to a validated, commercially viable diagnostic platform.